As #ESMO2024 draws to a close, it's clear that even as #oncology enters the second half of the second decade of being the world's most valuable therapy area, the innovative pipeline for cancer therapies remains exceptionally strong, with exciting new MoAs emerging in bispecifics, anti-body-drug conjugates, and radioligands. However, pipeline promise needs to translate to commercial reality for success. Find out more in our exciting webinar on September 26th, where we'll be talking the oncology pipe and oncology #LaunchExcellence - register now!
Take a deep dive into the evolving #oncology innovation area. Expect insights into how to navigate this fast-paced environment and how to achieve oncology launch excellence, and learn from real life case studies. Register today: https://bit.ly/3Zh56x7
